Future efforts are anticipated to therapeutically explore the potential of our findings in diseases marked by increased IL-17A levels and platelet reactivity or angiogenic responses, such as rheumatoid arthritis, atherosclerosis, psoriasis, cancer and myocardial infarction. This evidence concerns the gene IL17A and atherosclerosis.